JOJO Ltd
531910JOJO Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is topping out (4 weeks in) while the P/E sits at the 53rd percentile of its own 9-year range. Underneath, the last four quarters read improving — profit +7,883.3% year on year, and 123% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
JOJO Ltd trades at ₹247, losing momentum at the top and 4 weeks into that stage. That is +9.7% against its own 200-day average. It sits at 70% of a 52-week range of ₹167 to ₹281. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks.
Today the stock is losing momentum at the top — week 4 of stage 3, confirmed. At ₹247 it trades +9.7% versus its 200-day average and sits at 70% of its 52-week range (₹167–₹281).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +6,434% while the NIFTY 500 moved +274% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 2 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
JOJO Ltd trades at 152.0× P/E, mid-range by its own standards (53rd percentile). Its long-run median P/E is 133.0×, measured across 9.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 152.0× is mid-range by its own standards (53rd percentile), against a long-run median of 133.0× measured over 9.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 3y, of the +100.4%/yr price move, ~+504.6%/yr came from earnings growth and ~−404.2 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
JOJO Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +448.2% | +521.5% | +188.6% | +71.4% |
| Profit | — | +725.2% | — | +88.4% |
| EPS | — | +504.6% | — | +53.7% |
| Share price | +28.7% | +100.4% | +151.2% | +50.3% |
4-Factor Sector Score
66.2/100 — rank 1 of 10 in Pharma - Others · 69% evidence confidence
JOJO Ltd scores 66.2 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 1. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 30 + 13.6 + 8.9 + 13.7 = 66.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
JOJO Ltd reported ₹12.6 Cr of revenue in the Mar 26 quarter, +781.1% year on year. That is the 4th straight quarter of year-on-year growth. Over 10 years it has compounded at 71.4% a year. The last full year, FY26, came in at ₹24.0 Cr. The last four reported quarters add to ₹24.0 Cr.
FY26 revenue came in at ₹24.0 Cr (+448.2% on the year), capping 10 years at 71.4% compound. The latest quarter (Mar 26) printed ₹12.6 Cr, +781.1% year on year — the 4th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +1,385.8% growth against the decade's 71.4% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +446.9% over the last 4 quarters against +122.5%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
JOJO Ltd's operating margin is 48.1% in the Mar 26 quarter, +115.2 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 13 fiscal years the operating margin has ranged −400.0% to 42.7%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 48.1%, +115.2 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −400.0%–42.7%, and FY26's 42.7% is the top of that band — a record year.
Why the margin moved: operating margin went +115.2 pp year on year while gross margin went +0.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
JOJO Ltd earned ₹4.8 Cr of net profit in the Mar 26 quarter, +7,883.3% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹5.6 Cr. The 10-year compound rate is 88.4%. That is 38.0% of the quarter's revenue. The same quarter a year earlier earned ₹0.1 Cr.
Mar 26 profit was ₹4.8 Cr, +7,883.3% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹5.6 Cr (null), and the 10-year compound rate is 88.4%.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 123% of JOJO Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹10.5 Cr of operating cash against ₹5.6 Cr of profit. After ₹14.0 Cr of capital spending, ₹−3.0 Cr was left as free cash.
FY26: operating cash of ₹10.5 Cr against reported profit of ₹5.6 Cr, leaving free cash of ₹−3.0 Cr after ₹14.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 123% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 123%: the cash cycle stretched 152 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 9.0× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
JOJO Ltd's cash conversion cycle runs 365 days in FY26, up from 213 days in FY21. Capital spending ran ₹36.0 Cr over the last 3 years. At FY26 sales of ₹24.0 Cr each day of that cycle holds about ₹0.1 Cr, so roughly ₹24.0 Cr sits inside the business at any moment.
FY26: debtors at 365 days (an asset-light business — no inventory to speak of) — for a full cycle of 365 days, looser than FY21's 213.
In money terms: at FY26 sales of ₹24.0 Cr, each day of the cycle holds about ₹0.1 Cr — so the 365-day loop keeps roughly ₹24.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹36.0 Cr over the last 3 fiscal years against ₹4.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹9.8 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
JOJO Ltd earns a ROCE of 17% in FY26. That is up from a trough of −4% in FY15. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 23.4% net margin on 0.30× asset turns.
FY26 ROCE is 17%, recovered from a FY15 trough of −4% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 23.4% net margin × 0.30× asset turns × 1.47× balance-sheet leverage ≈ 10.3% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
JOJO Ltd carries ₹3.2 Cr of borrowings against ₹54.2 Cr of equity in FY26, a debt-to-equity of 0.06. Over 5 years borrowings went from ₹0.1 Cr to ₹3.2 Cr. Capital spending ran ₹36.0 Cr across the last 3 of those years.
FY26: borrowings of ₹3.2 Cr against equity of ₹54.2 Cr — a debt-to-equity of 0.06. Over 5 years borrowings went from ₹0.1 Cr to ₹3.2 Cr while capital spending ran ₹36.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 2.7 points of JOJO Ltd over 8 quarters, the biggest move on the register. That takes promoters to 67.8% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +2.7 points over 8 quarters to 67.8%.
Why the register moved: promoters drove it (+2.7 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
JOJO Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1JOJO Ltdthis page531910 | 66.2/100Favorable setup69% evidence | TURNING | 30.0/35 Revenue 100% · PAT 100% · OPM change 115.2 pp 95% evidence | 13.6/25 ROCE 17% · OPM 48.1% 76% evidence | 8.9/20 P/E 152× · PEG — 15% evidence | 13.7/20 RS sector 4.3% · RS bench 9.9% · 1Y 21%1 of 10 weeks ahead 70% evidence |
| Exact sum: 30 + 13.6 + 8.9 + 13.7 = 66.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Shukra Pharmaceuticals LtdSHUKRAPHAR | 65.3/100Favorable setup65% evidence | 21.8/35 Revenue 100% · PAT 100% · OPM change 32 pp 83% evidence | 17.2/25 ROCE 21.8% · OPM 69% 76% evidence | 9.3/20 P/E 62.2× · PEG — 15% evidence | 17.0/20 RS sector 49.8% · RS bench 40.2% · 1Y 112.2%9 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 21.8 + 17.2 + 9.3 + 17 = 65.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sun Pharma Advanced Research Company LtdSPARC | 64.1/100Mixed-positive evidence79% evidence | LEADER | 17.7/35 Revenue 100% · PAT 100% · OPM change 292 pp 71% evidence | 19.2/25 ROCE 164% · OPM 96% 95% evidence | 9.2/20 P/E 4.3× · PEG — 50% evidence | 18.0/20 RS sector 15.9% · RS bench 30.5% · 1Y 36%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.7 + 19.2 + 9.2 + 18 = 64.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Remus Pharmaceuticals LtdREMUS | 51.5/100Mixed-positive evidence70% evidence | FADING | 19.8/35 Revenue 100% · PAT 100% · OPM change 0 pp 48% evidence | 13.9/25 ROCE 16.8% · OPM 7% 95% evidence | 12.1/20 P/E 22.9× · PEG — 50% evidence | 5.7/20 RS sector -14.9% · RS bench -2.5% · 1Y -26.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 13.9 + 12.1 + 5.7 = 51.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Jenburkt Pharmaceuticals Ltd524731 | 50.6/100Mixed-positive evidence82% evidence | 16.9/35 Revenue 11.8% · PAT 6.1% · OPM change 6 pp 95% evidence | 19.7/25 ROCE 27.2% · OPM 32% 76% evidence | 10.1/20 P/E 13.2× · PEG — 50% evidence | 3.9/20 RS sector -15.3% · RS bench 0.4% · 1Y -14.7%5 of 7 weeks ahead to 2026-06-28 100% evidence | |
| Exact sum: 16.9 + 19.7 + 10.1 + 3.9 = 50.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Syncom Formulations (India) LtdSYNCOMF | 49.3/100Mixed-negative evidence87% evidence | ASLEEP | 20.9/35 Revenue 4.9% · PAT 54% · OPM change 4 pp 95% evidence | 17.3/25 ROCE 26.8% · OPM 16% 95% evidence | 11.1/20 P/E 16.1× · PEG — 50% evidence | 0.0/20 RS sector -23.1% · RS bench -11.6% · 1Y -27.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 17.3 + 11.1 + 0 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Madhuveer Com 18 Network LtdMADHUVEER | 47.0/100Mixed-negative evidence65% evidence | 15.6/35 Revenue 68.7% · PAT 12.8% · OPM change 18.4 pp 83% evidence | 8.6/25 ROCE -1.1% · OPM 69.7% 76% evidence | 8.5/20 P/E 660× · PEG — 15% evidence | 14.3/20 RS sector 14.3% · RS bench 6.3% · 1Y 11.7%12 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 15.6 + 8.6 + 8.5 + 14.3 = 47 · Decision use: Price leads the evidence: RS versus the benchmark is 6.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 8Unichem Laboratories LtdUNICHEMLAB | 42.2/100Mixed-negative evidence75% evidence | BREAKING OUT | 10.3/35 Revenue 4.4% · PAT 83.3% · OPM change -6 pp 95% evidence | 6.3/25 ROCE 4.1% · OPM 8% 76% evidence | 9.6/20 P/E 44.1× · PEG — 15% evidence | 16.0/20 RS sector 2.7% · RS bench 17.4% · 1Y -19%9 of 12 weeks ahead 100% evidence |
| Exact sum: 10.3 + 6.3 + 9.6 + 16 = 42.2 · Decision use: Price leads the evidence: RS versus the benchmark is 17.4%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Panacea Biotec LtdPANACEABIO | 39.0/100Mixed-negative evidence65% evidence | TURNING | 20.4/35 Revenue 14.4% · PAT 17.9% · OPM change 21.8 pp 74% evidence | 0.3/25 ROCE -2.4% · OPM 1.5% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.3/20 RS sector -10.2% · RS bench 2.1% · 1Y 0.8%10 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 0.3 + 10 + 8.3 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10TTK Healthcare LtdTTKHLTCARE | 38.2/100Mixed-negative evidence81% evidence | TURNING | 10.4/35 Revenue 7% · PAT -19.5% · OPM change -1 pp 95% evidence | 8.3/25 ROCE 8% · OPM 5% 95% evidence | 13.8/20 P/E 21.1× · PEG — 50% evidence | 5.7/20 RS sector -20.5% · RS bench 0.4% · 1Y -20.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 10.4 + 8.3 + 13.8 + 5.7 = 38.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is JOJO Ltd's share price today?
JOJO Ltd trades at ₹247, +28.7% over the past year. The company is valued at ₹852 Cr. The stock sits at 70% of its 52-week range of ₹167–₹281, +9.7% versus its 200-day average. On the tape, the price is topping out, 4 weeks in. — as of 31 July 2026.
What were JOJO Ltd's latest quarterly results?
JOJO Ltd reported revenue of ₹12.6 Cr and net profit of ₹4.8 Cr for the Mar 26 quarter. Revenue rose 781.1% and profit rose 7,883.3% year on year. Earnings per share were ₹1.88. The operating margin was 48.1%, 115.2 pp higher than a year earlier. — as of 31 July 2026.
What is JOJO Ltd's revenue?
JOJO Ltd reported revenue of ₹12.6 Cr in the Mar 26 quarter, +781.1% year on year. For the full FY26 fiscal year, revenue was ₹24.0 Cr (+448.2%). Over the last 10 years revenue compounded at 71.4% a year. — as of 31 July 2026.
What is JOJO Ltd's profit?
JOJO Ltd earned ₹4.8 Cr of net profit in the Mar 26 quarter, +7,883.3% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹5.6 Cr. The operating margin ran 48.1% in the latest quarter. — as of 31 July 2026.
What is JOJO Ltd's market cap?
JOJO Ltd's market capitalisation is ₹852 Cr at a share price of ₹247. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is JOJO Ltd's P/E ratio?
JOJO Ltd trades at a P/E of 152.0×, at the 53rd percentile of its own 9-year range, against a long-run median of 133.0×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does JOJO Ltd pay a dividend?
Yes — JOJO Ltd's dividend payout was 2% of profit in FY26, and it recorded a payout in 1 of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is JOJO Ltd overvalued?
On its own history, JOJO Ltd looks mid-range against its own history: its P/E of 152.0× sits at the 53rd percentile of its 9-year range (long-run median 133.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 31 July 2026.
Is JOJO Ltd growing?
Yes — JOJO Ltd is growing: latest-quarter revenue +781.1% year on year, profit +7,883.3%, and the margin +115.2 pp at 48.1%. The 10-year compound rates are 71.4% (revenue) and 88.4% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is JOJO Ltd performing?
JOJO Ltd is topping out, 4 weeks in. Its latest quarter's revenue rose 781.1% and profit rose 7,883.3% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
Is JOJO Ltd in an uptrend?
It is stalling — the price is topping out (week 4 of stage 3), trading +9.7% versus its 200-day average and at 70% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is JOJO Ltd beating the market?
On recent form, yes — JOJO Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 2 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +6,434% against the NIFTY 500's +274% — ahead of the index over the full window. — as of 31 July 2026.
Will JOJO Ltd's share price go up?
This page publishes no price forecast for JOJO Ltd. What it measures instead: the share price is ₹247, the price is topping out 4 weeks in. Its P/E of 152.0× sits at the 53rd percentile of its own 9-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns JOJO Ltd?
Promoters hold 67.8% of JOJO Ltd, foreign institutions null%, domestic institutions null% and the public 32.2% (latest quarter). The biggest move on the register over the last two years: Promoters added 2.7 points over 8 quarters. — as of 31 July 2026.
Does JOJO Ltd have too much debt?
No — JOJO Ltd's debt-to-equity is 0.06, and operating profit covers the interest bill −8×. FY26 borrowings were ₹3.2 Cr against equity of ₹54.2 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is JOJO Ltd's capex?
JOJO Ltd spent ₹36.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹14.0 Cr, with ₹9.8 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is JOJO Ltd's cash flow?
JOJO Ltd generated ₹10.5 Cr of operating cash flow in FY26 and ₹−3.0 Cr of free cash flow after ₹14.0 Cr of capital spending. Reported profit that year was ₹5.6 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is JOJO Ltd's profit real cash?
Yes — over the last 3 fiscal years, 123% of JOJO Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹10.5 Cr against reported profit of ₹5.6 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is JOJO Ltd in its business cycle?
JOJO Ltd's FY26 operating margin was 42.7%, against a 13-year band of −400.0%–42.7%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 48.1%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the JOJO Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is JOJO Ltd a stock worth studying right now?
This is not investment advice. The machine read: JOJO Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.